Psychiatry - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/232

Filters

2017 - 2019 1 2020 - 2023 1
2
Reset filters

Settings
Statistics
Citations
Author: Ayton, Scott × Author: Pantelis, Christos × Start date: 2009 ×

Search Results

Now showing 1 - 2 of 2
  • Item
    No Preview Available
    Perturbed iron biology in the prefrontal cortex of people with schizophrenia
    Lotan, A ; Luza, S ; Opazo, CM ; Ayton, S ; Lane, DJR ; Mancuso, S ; Pereira, A ; Sundram, S ; Weickert, CS ; Bousman, C ; Pantelis, C ; Everall, IP ; Bush, AI (SPRINGERNATURE, 2023-05)
    Despite loss of grey matter volume and emergence of distinct cognitive deficits in young adults diagnosed with schizophrenia, current treatments for schizophrenia do not target disruptions in late maturational reshaping of the prefrontal cortex. Iron, the most abundant transition metal in the brain, is essential to brain development and function, but in excess, it can impair major neurotransmission systems and lead to lipid peroxidation, neuroinflammation and accelerated aging. However, analysis of cortical iron biology in schizophrenia has not been reported in modern literature. Using a combination of inductively coupled plasma-mass spectrometry and western blots, we quantified iron and its major-storage protein, ferritin, in post-mortem prefrontal cortex specimens obtained from three independent, well-characterised brain tissue resources. Compared to matched controls (n = 85), among schizophrenia cases (n = 86) we found elevated tissue iron, unlikely to be confounded by demographic and lifestyle variables, by duration, dose and type of antipsychotic medications used or by copper and zinc levels. We further observed a loss of physiologic age-dependent iron accumulation among people with schizophrenia, in that the iron level among cases was already high in young adulthood. Ferritin, which stores iron in a redox-inactive form, was paradoxically decreased in individuals with the disorder. Such iron-ferritin uncoupling could alter free, chemically reactive, tissue iron in key reasoning and planning areas of the young-adult schizophrenia cortex. Using a prediction model based on iron and ferritin, our data provide a pathophysiologic link between perturbed cortical iron biology and schizophrenia and indicate that achievement of optimal cortical iron homeostasis could offer a new therapeutic target.
  • Item
    Thumbnail Image
    Lithium suppression of tau induces brain iron accumulation and neurodegeneration
    Lei, P ; Ayton, S ; Appukuttan, AT ; Moon, S ; Duce, JA ; Volitakis, I ; Cherny, R ; Wood, SJ ; Greenough, M ; Berger, G ; Pantelis, C ; McGorry, P ; Yung, A ; Finkelstein, DI ; Bush, AI (NATURE PUBLISHING GROUP, 2017-03)
    Lithium is a first-line therapy for bipolar affective disorder. However, various adverse effects, including a Parkinson-like hand tremor, often limit its use. The understanding of the neurobiological basis of these side effects is still very limited. Nigral iron elevation is also a feature of Parkinsonian degeneration that may be related to soluble tau reduction. We found that magnetic resonance imaging T2 relaxation time changes in subjects commenced on lithium therapy were consistent with iron elevation. In mice, lithium treatment lowers brain tau levels and increases nigral and cortical iron elevation that is closely associated with neurodegeneration, cognitive loss and parkinsonian features. In neuronal cultures lithium attenuates iron efflux by lowering tau protein that traffics amyloid precursor protein to facilitate iron efflux. Thus, tau- and amyloid protein precursor-knockout mice were protected against lithium-induced iron elevation and neurotoxicity. These findings challenge the appropriateness of lithium as a potential treatment for disorders where brain iron is elevated (for example, Alzheimer's disease), and may explain lithium-associated motor symptoms in susceptible patients.